Igor N. Samartsev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Igor N. Samartsev has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Sergey A. Zhivolupov
Kirov Military Medical Academy
21 shared publications - M.S. Parshin
City Hospital No. 26
5 shared publications - Igor’ Vyacheslavovich Litvinenko
S.M. Kirov Military Medical Academy
3 shared publications - Kamil Magomedovich Magomedov
Clinical Hospital of St. Luka
3 shared publications - M. N. Markova
Military Medical Academy n.a. S.M. Kirov
3 shared publications - R. Z. Nazhmudinov
Saints Luke’s Clinical Hospital, Center for Medical Rehabilitation
3 shared publications
Latest Publications
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Assessment of adherence to nootropic medications in neurological patients. (APRIORI study)
Objective. To identify factors that neurologists consider determinants of adherence to nootropic medications in patients with neurological disorders. Material and methods. This cross-sectional descriptive study included 122 neurologists from St. Petersburg and the Leningrad Region. Participants completed a treatment adherence (TA) questionnaire comprising 30 statements divided into four domains: disease-related, patient-related, physician-related, and medication-related factors. Respondents rated their agreement with each statement using a 5-point Likert scale. The most significant statement in each category was identified. Results. The key factors negatively influencing adherence to nootropic medications were the chronic nature of the disease (χ2=8.40; p=0.14), exposure to negative information about the physician online (χ2=17.03; p=0.004), and the requirement for multiple daily doses (χ2=25.03; p=0.0009). In contrast, advanced age was associated with improved adherence to nootropic therapy (χ2=47.27; p=0.0014). Conclusion. Neurologists identified the requirement for multiple daily dosing as a primary contributor to low adherence to nootropic therapy. This barrier may be mitigated by prescribing nootropics with prolonged-release formulations that permit once-daily administration. Other barriers, such as the chronic course of the disease and patient age, are non-modifiable, whereas negative information about the physician online is challenging to address.
- 3 November 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (10)
Assessment of adherence to nootropic medications in neurological patients. (APRIORI study)
Objective. To identify factors that neurologists consider determinants of adherence to nootropic medications in patients with neurological disorders. Material and methods. This cross-sectional descriptive study included 122 neurologists from St. Petersburg and the Leningrad Region. Participants completed a treatment adherence (TA) questionnaire comprising 30 statements divided into four domains: disease-related, patient-related, physician-related, and medication-related factors. Respondents rated their agreement with each statement using a 5-point Likert scale. The most significant statement in each category was identified. Results. The key factors negatively influencing adherence to nootropic medications were the chronic nature of the disease (χ2=8.40; p=0.14), exposure to negative information about the physician online (χ2=17.03; p=0.004), and the requirement for multiple daily doses (χ2=25.03; p=0.0009). In contrast, advanced age was associated with improved adherence to nootropic therapy (χ2=47.27; p=0.0014). Conclusion. Neurologists identified the requirement for multiple daily dosing as a primary contributor to low adherence to nootropic therapy. This barrier may be mitigated by prescribing nootropics with prolonged-release formulations that permit once-daily administration. Other barriers, such as the chronic course of the disease and patient age, are non-modifiable, whereas negative information about the physician online is challenging to address.
- Open Access
- 5 July 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (2) , 111-118
Pathophysiological Basis and Clinical Significance of Neuroplastic Changes of the Spinal Cord in the Formation of Phantom Pain Syndrome
Phantom pain syndrome, which occurs in a significant proportion of patients after limb amputation, is a pathophysiologically complex pain phenomenon that significantly reduces the quality of life of patients. Recent data have convincingly proved that neuroplastic changes in the spinal cord are a critically important early link in the pathogenesis of this pathology. This review presents an analysis of current understanding of the pathophysiological basis of spinal neuroplasticity in phantom pain syndrome after traumatic amputation. The contribution of central sensitization, structural reorganization and neuroinflammation to the formation of specific symptoms of the disease (spontaneous and stimulus-induced pain, somatotopic reorganization, etc.) is discussed. Special attention is paid to the analysis of the clinical significance of the discussed pathophysiological processes: from explaining the effectiveness of existing treatment methods to the prospects for the development of new targeted strategies aimed at modulating spinal neuroplasticity for the prevention of the development and therapy of the formed phantom pain syndrome.
- 5 July 2026
- Published by National Medical Research Center for Childrens Health in L.O. Badalyan Neurological Journal
- Vol. 7 (2) , 111-118
Open AccessPathophysiological Basis and Clinical Significance of Neuroplastic Changes of the Spinal Cord in the Formation of Phantom Pain Syndrome
Phantom pain syndrome, which occurs in a significant proportion of patients after limb amputation, is a pathophysiologically complex pain phenomenon that significantly reduces the quality of life of patients. Recent data have convincingly proved that neuroplastic changes in the spinal cord are a critically important early link in the pathogenesis of this pathology. This review presents an analysis of current understanding of the pathophysiological basis of spinal neuroplasticity in phantom pain syndrome after traumatic amputation. The contribution of central sensitization, structural reorganization and neuroinflammation to the formation of specific symptoms of the disease (spontaneous and stimulus-induced pain, somatotopic reorganization, etc.) is discussed. Special attention is paid to the analysis of the clinical significance of the discussed pathophysiological processes: from explaining the effectiveness of existing treatment methods to the prospects for the development of new targeted strategies aimed at modulating spinal neuroplasticity for the prevention of the development and therapy of the formed phantom pain syndrome.
- 30 June 2026
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 7,p. 1171-1181
Clinical and neurophysiological assessment of efficacy of early use of polypeptide neurorepair agents in comprehensive therapy of facial nerve neuropathy
The article presents the results of comprehensive treatment of patients with facial nerve neuropathy against the background of comorbid conditions using polypeptide neuroreparants. The data of dynamic clinical and instrumental examination of patients with facial paresis of varying severity are provided. The role of neuropeptide support in overcoming the «regenerative plateau» and accelerating the reinnervation of facial muscles is substantiated. A positive trend in functional recovery was revealed, as assessed by the House — Brackmann Scale and the MRC (Medical Research Council) Muscle Scale. The data of stimulatory electroneuromyography confirm a statistically significant increase in the M — response amplitude and a reduction in distal latency in patients of the main group. The efficacy of the proposed algorithm in minimizing the risks of developing pathological synkinesias and improving the quality of life according to the EQ — 5D — 5L index is demonstrated. The feasibility of including repeated courses of neuroreparative therapy in rehabilitation programs for patients with lesions of the peripheral part of the facial nerve has been proven.
- 30 June 2026
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 7,p. 1171-1181
Clinical and neurophysiological assessment of efficacy of early use of polypeptide neurorepair agents in comprehensive therapy of facial nerve neuropathy
The article presents the results of comprehensive treatment of patients with facial nerve neuropathy against the background of comorbid conditions using polypeptide neuroreparants. The data of dynamic clinical and instrumental examination of patients with facial paresis of varying severity are provided. The role of neuropeptide support in overcoming the «regenerative plateau» and accelerating the reinnervation of facial muscles is substantiated. A positive trend in functional recovery was revealed, as assessed by the House — Brackmann Scale and the MRC (Medical Research Council) Muscle Scale. The data of stimulatory electroneuromyography confirm a statistically significant increase in the M — response amplitude and a reduction in distal latency in patients of the main group. The efficacy of the proposed algorithm in minimizing the risks of developing pathological synkinesias and improving the quality of life according to the EQ — 5D — 5L index is demonstrated. The feasibility of including repeated courses of neuroreparative therapy in rehabilitation programs for patients with lesions of the peripheral part of the facial nerve has been proven.
- 5 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (5) , 108-114
Efficacy and tolerability of the pharmaconutraceutical complex Theraflex Ultra in the treatment of patients with chronic non-specific lower back pain due toprimarily discogenic pathology (FORSAGE study)
Objective. To evaluate the efficacy and tolerability of the pharmaconutraceutical complex, Theraflex Ultra, based on undenatured (native) type II collagen, in the treatment of discogenic chronic low back pain (CLBP). Material and methods. This open, multicenter, observational study included 50 patients (28 women and 22 men; mean age 48.3 years [45.5; 52.2]) diagnosed with CLBP, mostly associated with discogenic pathology, as confirmed by clinical evaluation and neuroimaging. The study group (n=25) received standard therapy comprising non-steroidal anti-inflammatory drugs (NSAIDs) for 10 days, a centrally acting muscle relaxant for 14 days, and a high-dose vitamin B complex for 21 days, combined with Theraflex Ultra at 2 capsules twice daily for 2 months. The control group (n=25) received only the standard therapy. Efficacy was assessed after 1, 2, and 3 months using various scales, including the Numeric Rating Scale for Pain (NRS-P), the Douleur Neuropathique 4 (DN4), the Back Pain Functional Scale (BPFS), and the Medical Outcomes Study Short Form 36 (MOS SF-36). The relapse rate during the first year post-enrollment in the study was also documented. Results. After one month, the study group exhibited a significantly greater reduction in pain intensity, as measured by the NRS-P, compared to the control group (23.2±8.8 versus 35.2±7.4; p<0.05). After two months, the study group demonstrated significant improvements in functional activity (BPFS: 51.7±15.7 vs. 40.2±13.1) and the physical component of quality of life (MOS SF-36: 86.8±5.5 vs. 77.2±8.1; p<0.05). No intergroup differences were noted on the DN4 scale, indicating nociceptive pain. Treatment adherence in the study group was high, with a score of 9.9±4.2 on the Adherence to Refills and Medications Scale (ARMS-7). A relapse occurred in 20% of patients in the study group and 32% in the control group after one year (relative risk [RR] 1.4 [confidence interval [CI] 0.513-3.824]; number needed to treat [NNT]=8.3). Adverse events were reported in all groups; however, they were mild and did not require treatment discontinuation. Conclusion. The addition of Theraflex Ultra to the standard therapy regimen for discogenic chronic non-specific low back pain yields a significant reduction in pain intensity, enhanced functional activity and quality of life, and a decreased risk of relapse within a year. The product demonstrates high treatment adherence and favorable tolerability. Subsequent randomized studies are warranted to validate these findings.
- 5 June 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (5) , 108-114
Efficacy and tolerability of the pharmaconutraceutical complex Theraflex Ultra in the treatment of patients with chronic non-specific lower back pain due toprimarily discogenic pathology (FORSAGE study)
Objective. To evaluate the efficacy and tolerability of the pharmaconutraceutical complex, Theraflex Ultra, based on undenatured (native) type II collagen, in the treatment of discogenic chronic low back pain (CLBP). Material and methods. This open, multicenter, observational study included 50 patients (28 women and 22 men; mean age 48.3 years [45.5; 52.2]) diagnosed with CLBP, mostly associated with discogenic pathology, as confirmed by clinical evaluation and neuroimaging. The study group (n=25) received standard therapy comprising non-steroidal anti-inflammatory drugs (NSAIDs) for 10 days, a centrally acting muscle relaxant for 14 days, and a high-dose vitamin B complex for 21 days, combined with Theraflex Ultra at 2 capsules twice daily for 2 months. The control group (n=25) received only the standard therapy. Efficacy was assessed after 1, 2, and 3 months using various scales, including the Numeric Rating Scale for Pain (NRS-P), the Douleur Neuropathique 4 (DN4), the Back Pain Functional Scale (BPFS), and the Medical Outcomes Study Short Form 36 (MOS SF-36). The relapse rate during the first year post-enrollment in the study was also documented. Results. After one month, the study group exhibited a significantly greater reduction in pain intensity, as measured by the NRS-P, compared to the control group (23.2±8.8 versus 35.2±7.4; p<0.05). After two months, the study group demonstrated significant improvements in functional activity (BPFS: 51.7±15.7 vs. 40.2±13.1) and the physical component of quality of life (MOS SF-36: 86.8±5.5 vs. 77.2±8.1; p<0.05). No intergroup differences were noted on the DN4 scale, indicating nociceptive pain. Treatment adherence in the study group was high, with a score of 9.9±4.2 on the Adherence to Refills and Medications Scale (ARMS-7). A relapse occurred in 20% of patients in the study group and 32% in the control group after one year (relative risk [RR] 1.4 [confidence interval [CI] 0.513-3.824]; number needed to treat [NNT]=8.3). Adverse events were reported in all groups; however, they were mild and did not require treatment discontinuation. Conclusion. The addition of Theraflex Ultra to the standard therapy regimen for discogenic chronic non-specific low back pain yields a significant reduction in pain intensity, enhanced functional activity and quality of life, and a decreased risk of relapse within a year. The product demonstrates high treatment adherence and favorable tolerability. Subsequent randomized studies are warranted to validate these findings.
- Open Access
- 19 March 2026
- Published by ECO-Vector LLC (Publications) in Bulletin of the Russian Military Medical Academy
- Vol. 28 (1) , 15-22
Electron microscopy of compression post-traumatic plexopathy in muscle and nerve biopsies
BACKGROUND: The substantial prevalence of peripheral nervous system injuries during peacetime and particularly during wartime, frequent disability among affected individuals, and extended hospitalization periods underscore the medical and social relevance of this issue. Traumatic plexopathies represent the most severe pathogenetic form of peripheral nervous system injuries, as they carry a high probability of resulting in serious neurological consequences with potential irreversible loss of function. The severity of traumatic plexopathy is primarily determined through correlation of clinical manifestations with electrophysiological, neuroimaging, and ultrasonographic data. Electron microscopy enables evaluation of myelin fibers in subcutaneous nerves, the structure of neuromuscular synapses, and the condition of organelles and inclusions within myofibers. Such detailed pathomorphological analysis of traumatic plexopathy provides a more comprehensive picture of pathological changes, enhances the effectiveness of ongoing therapy, and facilitates the development of novel therapeutic approaches for this condition. AIM: This study aimed to perform electron microscopic analysis of subcutaneous nerves and muscles in three patients with traumatic (compressive) brachial plexopathy treated at a neurology clinic. METHODS: Biopsy samples of the suprascapular and deltoid muscles and nerves, obtained surgically under local anesthesia, were prepared for electron microscopy using standard techniques. After contrasting, ultra-thin sections were photographed in a transmission electron microscope, and after scanning the electron micrographs, the structure of nerve fibers and myofibers was described in detail. RESULTS: Examination of myelinated fibers in subcutaneous nerve biopsies revealed distinct ultrastructural degenerative changes. In the myofibers, in addition to myolysis, mitochondrial dysfunction and metabolic myopathy were identified as manifestations of denervation resulting from impaired neural regulation caused by neuromuscular synapse destruction. This synaptic destruction may cause metabolic and structural disturbances in the myofibers as well as deterioration of their functional activity. CONCLUSION: This electron microscopic study of biopsy samples from the brachial plexus nerves and shoulder girdle muscles revealed key morphological features of structural impairments in compressive plexopathy, which may serve as a basis for improving treatment efficacy in these patients.
- 19 March 2026
- Published by ECO-Vector LLC (Publications) in Bulletin of the Russian Military Medical Academy
- Vol. 28 (1) , 15-22
Open AccessElectron microscopy of compression post-traumatic plexopathy in muscle and nerve biopsies
BACKGROUND: The substantial prevalence of peripheral nervous system injuries during peacetime and particularly during wartime, frequent disability among affected individuals, and extended hospitalization periods underscore the medical and social relevance of this issue. Traumatic plexopathies represent the most severe pathogenetic form of peripheral nervous system injuries, as they carry a high probability of resulting in serious neurological consequences with potential irreversible loss of function. The severity of traumatic plexopathy is primarily determined through correlation of clinical manifestations with electrophysiological, neuroimaging, and ultrasonographic data. Electron microscopy enables evaluation of myelin fibers in subcutaneous nerves, the structure of neuromuscular synapses, and the condition of organelles and inclusions within myofibers. Such detailed pathomorphological analysis of traumatic plexopathy provides a more comprehensive picture of pathological changes, enhances the effectiveness of ongoing therapy, and facilitates the development of novel therapeutic approaches for this condition. AIM: This study aimed to perform electron microscopic analysis of subcutaneous nerves and muscles in three patients with traumatic (compressive) brachial plexopathy treated at a neurology clinic. METHODS: Biopsy samples of the suprascapular and deltoid muscles and nerves, obtained surgically under local anesthesia, were prepared for electron microscopy using standard techniques. After contrasting, ultra-thin sections were photographed in a transmission electron microscope, and after scanning the electron micrographs, the structure of nerve fibers and myofibers was described in detail. RESULTS: Examination of myelinated fibers in subcutaneous nerve biopsies revealed distinct ultrastructural degenerative changes. In the myofibers, in addition to myolysis, mitochondrial dysfunction and metabolic myopathy were identified as manifestations of denervation resulting from impaired neural regulation caused by neuromuscular synapse destruction. This synaptic destruction may cause metabolic and structural disturbances in the myofibers as well as deterioration of their functional activity. CONCLUSION: This electron microscopic study of biopsy samples from the brachial plexus nerves and shoulder girdle muscles revealed key morphological features of structural impairments in compressive plexopathy, which may serve as a basis for improving treatment efficacy in these patients.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 141-147
An open-label observational study of the efficacy and tolerability of rapidly dissolving forms of aceclofenac and nimesulide for oral use in the treatment of patients with acute non-specific low back pain (ASTRA study)
Objective. To analyze the efficacy and tolerability of aceclofenac in powder and nimesulide in granules for the preparation of a suspension for oral administration in the treatment of patients with acute nonspecific low back pain (ANLP). Material and methods. The study involved 60 patients (37 women and 23 men), average age 49.6 [44.1; 54.9] years, divided into 2 groups: group 1 (n=30) aceclofenac 200 mg/day 10 days; group 2 (n=30) nimesulide 200 mg/day 10 days. All patients received basic treatment, including an oral centrally acting muscle relaxant for 14 days and B vitamins for 21 days. Within the framework of 3 visits (start of treatment, 14, 21 days) NRS pain scale, DN4 Questionnaire, Back Pain Functional Scale (BPFS), MOS SF-36 “The Medical Outcomes Study 36-Item Short-Form Health Survey”, ARMS-7 (Adherence to Refills and Medications Scale) and safety aspects were analyzed. To analyze the characteristics of the efficacy and tolerability of NSAIDs in the form of powder/granules for the preparation of oral suspension, a retrospective survey was conducted among 200 patients with non-specific low back pain. Results. After 14 and 21 days, both groups demonstrated a significant reduction in pain intensity, its neuropathic component, improved functional activity, and high treatment adherence without significant differences between the groups. Aceclofenac relieved acute pain much faster than nimesulide (63.2±4.2 vs. 85.4±4.5, p<0.01). Both NSAIDs were safe without significant differences between the study groups. In the retrospective part of the study, all participants stated that they had used NSAIDs in the form of powder/granules for the preparation of an oral suspension at least once. The most significant advantages of this drug form were the rapid onset of effect (62.5%), ease of administration (56%), and low risk of adverse gastrointestinal events (44.5%). 72.5% of patients recommend taking NSAIDs in the form of powder/granules for the preparation of an oral suspension. Conclusion. The use of aceclofenac and nimesulide in a rapidly dissolving form for the preparation of a suspension for oral administration is an effective and safe option for the treatment of ANLP. Rapid onset of effect, ease of administration, and a favorable safety profile are important advantages of this NSAID formulation for patients. Aceclofenac in the form of a powder for the preparation of a suspension for oral administration is superior to rapidly dissolving nimesulide in the speed of pain relief and can be considered as a first-line treatment for patients with ANLP.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 141-147
An open-label observational study of the efficacy and tolerability of rapidly dissolving forms of aceclofenac and nimesulide for oral use in the treatment of patients with acute non-specific low back pain (ASTRA study)
Objective. To analyze the efficacy and tolerability of aceclofenac in powder and nimesulide in granules for the preparation of a suspension for oral administration in the treatment of patients with acute nonspecific low back pain (ANLP). Material and methods. The study involved 60 patients (37 women and 23 men), average age 49.6 [44.1; 54.9] years, divided into 2 groups: group 1 (n=30) aceclofenac 200 mg/day 10 days; group 2 (n=30) nimesulide 200 mg/day 10 days. All patients received basic treatment, including an oral centrally acting muscle relaxant for 14 days and B vitamins for 21 days. Within the framework of 3 visits (start of treatment, 14, 21 days) NRS pain scale, DN4 Questionnaire, Back Pain Functional Scale (BPFS), MOS SF-36 “The Medical Outcomes Study 36-Item Short-Form Health Survey”, ARMS-7 (Adherence to Refills and Medications Scale) and safety aspects were analyzed. To analyze the characteristics of the efficacy and tolerability of NSAIDs in the form of powder/granules for the preparation of oral suspension, a retrospective survey was conducted among 200 patients with non-specific low back pain. Results. After 14 and 21 days, both groups demonstrated a significant reduction in pain intensity, its neuropathic component, improved functional activity, and high treatment adherence without significant differences between the groups. Aceclofenac relieved acute pain much faster than nimesulide (63.2±4.2 vs. 85.4±4.5, p<0.01). Both NSAIDs were safe without significant differences between the study groups. In the retrospective part of the study, all participants stated that they had used NSAIDs in the form of powder/granules for the preparation of an oral suspension at least once. The most significant advantages of this drug form were the rapid onset of effect (62.5%), ease of administration (56%), and low risk of adverse gastrointestinal events (44.5%). 72.5% of patients recommend taking NSAIDs in the form of powder/granules for the preparation of an oral suspension. Conclusion. The use of aceclofenac and nimesulide in a rapidly dissolving form for the preparation of a suspension for oral administration is an effective and safe option for the treatment of ANLP. Rapid onset of effect, ease of administration, and a favorable safety profile are important advantages of this NSAID formulation for patients. Aceclofenac in the form of a powder for the preparation of a suspension for oral administration is superior to rapidly dissolving nimesulide in the speed of pain relief and can be considered as a first-line treatment for patients with ANLP.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 154-160
Contemporary concepts of the rational use of centrally acting skeletal muscle relaxants in the treatment of vertebrogenic dorsalgia
Centrally acting skeletal muscle relaxants (CMs) in combination with nonsteroidal anti-inflammatory drugs and vitamins B are among the most frequently prescribed medications for the treatment of dorsalgia. Despite belonging to the same clinical and pharmacological group, CMs differ from each other in both their mechanism of action and the range of adverse effects. The emergence of new CMs in clinical practice demonstrates the growing innovation of this class of pharmacological agents in the treatment of musculoskeletal pain, necessitating a detailed study of the competitive advantages of individual CMs to improve treatment efficacy and safety.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 154-160
Contemporary concepts of the rational use of centrally acting skeletal muscle relaxants in the treatment of vertebrogenic dorsalgia
Centrally acting skeletal muscle relaxants (CMs) in combination with nonsteroidal anti-inflammatory drugs and vitamins B are among the most frequently prescribed medications for the treatment of dorsalgia. Despite belonging to the same clinical and pharmacological group, CMs differ from each other in both their mechanism of action and the range of adverse effects. The emergence of new CMs in clinical practice demonstrates the growing innovation of this class of pharmacological agents in the treatment of musculoskeletal pain, necessitating a detailed study of the competitive advantages of individual CMs to improve treatment efficacy and safety.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 66-74
A contemporary view on the problem of pathogenesis and treatment of phantom pain syndrome
Phantom pain syndrome (PPS) occurs after the amputation of various organs, most commonly limbs, and is associated with maladaptive neuroplastic changes in the peripheral and central nervous systems. Since the first description of PPS clinical features by the French military surgeon Ambroise Paré in the 16th century, the number of studies on this issue has grown annually. However, despite significant advances in understanding the mechanisms of PPS development, clear predictors of its onset is still unknown, and the effectiveness of current therapies remains insufficient. Treatment requires a multimodal approach combining pharmacotherapy (including antidepressants, gabapentin), non-pharmacological methods, and interventional procedures.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 66-74
A contemporary view on the problem of pathogenesis and treatment of phantom pain syndrome
Phantom pain syndrome (PPS) occurs after the amputation of various organs, most commonly limbs, and is associated with maladaptive neuroplastic changes in the peripheral and central nervous systems. Since the first description of PPS clinical features by the French military surgeon Ambroise Paré in the 16th century, the number of studies on this issue has grown annually. However, despite significant advances in understanding the mechanisms of PPS development, clear predictors of its onset is still unknown, and the effectiveness of current therapies remains insufficient. Treatment requires a multimodal approach combining pharmacotherapy (including antidepressants, gabapentin), non-pharmacological methods, and interventional procedures.
- Open Access
- 21 October 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (5) , 141-151
Complex therapy of musculoskeletal pain: the role of centrally acting muscle relaxants
Chronic pain is the main manifestation of musculoskeletal diseases (MSDs), leading to deterioration of quality of life and loss of ability to work. The importance of this problem is determined by the widespread prevalence of MSDs, osteoarthritis (OA), acute and chronic non-specific back pain (NBP), periarticular soft tissues lesions. Introduction of effective methods of treatment of musculoskeletal pain (MSP) into medical practice is one of the fundamental tasks of modern medicine.The pathogenesis of MSP includes mechanisms such as injury, inflammation, peripheral sensitization, biomechanical disorders, dysfunction of the nociceptive system and psychoemotional disorders. Painful muscle tension plays an important role in the development of MSP, especially in NBP. Given the complex pathogenesis of MSP, its treatment is based on the combined use of drugs with different mechanisms of action and nonpharmacological methods. Non-steroidal anti-inflammatory drugs (NSAIDs) have a central place in this context. However, they can cause serious adverse reactions (ARs), so when choosing NSAIDs, it is necessary to consider comorbid pathology and risk factors. One of the most acceptable NSAIDs with a pronounced analgesic effect and low incidence of ARs is aceclofenac, which is available in various dosage forms (tablets, sachets, topical cream for external use). This medication is characterized by proven efficacy and good tolerability.Centrally acting muscle relaxants (CM) play an important role in the treatment of MSP. They eliminate muscle spasm, enhance the effect of analgesics and reduce the need for NSAIDs. The effect of CM has been demonstrated in spasticity and NBP. However, the use of many drugs of this group can be associated with serious ARs, which limits their use.Tolperisone has the best combination of efficacy and favorable safety profile among CM. Its positive effect in the complex treatment of NBP has been confirmed in several well-organized, placebo-controlled trials. There are also studies demonstrating the efficacy of tolperisone in OA. An important advantage of this drug is virtually no sedative effect, and no negative impact on hemodynamics and on the ability to perform concentration-intensive work. Emergence of a new form of tolperisone – extended-release tablets (Mydocalm® Long 450 mg) – increases patient compliance with CM therapy and facilitates the physician's work.
- 21 October 2024
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (5) , 141-151
Open AccessComplex therapy of musculoskeletal pain: the role of centrally acting muscle relaxants
Chronic pain is the main manifestation of musculoskeletal diseases (MSDs), leading to deterioration of quality of life and loss of ability to work. The importance of this problem is determined by the widespread prevalence of MSDs, osteoarthritis (OA), acute and chronic non-specific back pain (NBP), periarticular soft tissues lesions. Introduction of effective methods of treatment of musculoskeletal pain (MSP) into medical practice is one of the fundamental tasks of modern medicine.The pathogenesis of MSP includes mechanisms such as injury, inflammation, peripheral sensitization, biomechanical disorders, dysfunction of the nociceptive system and psychoemotional disorders. Painful muscle tension plays an important role in the development of MSP, especially in NBP. Given the complex pathogenesis of MSP, its treatment is based on the combined use of drugs with different mechanisms of action and nonpharmacological methods. Non-steroidal anti-inflammatory drugs (NSAIDs) have a central place in this context. However, they can cause serious adverse reactions (ARs), so when choosing NSAIDs, it is necessary to consider comorbid pathology and risk factors. One of the most acceptable NSAIDs with a pronounced analgesic effect and low incidence of ARs is aceclofenac, which is available in various dosage forms (tablets, sachets, topical cream for external use). This medication is characterized by proven efficacy and good tolerability.Centrally acting muscle relaxants (CM) play an important role in the treatment of MSP. They eliminate muscle spasm, enhance the effect of analgesics and reduce the need for NSAIDs. The effect of CM has been demonstrated in spasticity and NBP. However, the use of many drugs of this group can be associated with serious ARs, which limits their use.Tolperisone has the best combination of efficacy and favorable safety profile among CM. Its positive effect in the complex treatment of NBP has been confirmed in several well-organized, placebo-controlled trials. There are also studies demonstrating the efficacy of tolperisone in OA. An important advantage of this drug is virtually no sedative effect, and no negative impact on hemodynamics and on the ability to perform concentration-intensive work. Emergence of a new form of tolperisone – extended-release tablets (Mydocalm® Long 450 mg) – increases patient compliance with CM therapy and facilitates the physician's work.
- 27 April 2024
- Published by Alfmed LLC in Medical alphabet
- No. 2,p. 26-32
Open-label observational study of effectiveness and tolerability of ipidacrine in treatment of patients with diabetic polyneuropathy (DIAMANT study)
Diabetic polyneuropathy (DPN) is one of the most common complications of diabetes mellitus, leading to the development of flaccid paresis, neuropathic pain syndrome, sensitive ataxia, as well as trophic disorders in the distal parts of the lower extremities.The purpose of the randomized, open-label, comparative, prospective study was to evaluate the effectiveness and tolerability of ipidacrine in the complex treatment of patients with DPN.Materials and methods. Patients with DPN (n = 60) were randomized into 2 groups. Both groups received basic therapy (alpha-lipoic acid, B vitamins, gabapentin); in the treatment of patients of the main group (n = 30), in addition, ipidacrine was used (Ipidacrine-SZ, North Star Co., Russia). We have analyzed the intensity of pain syndrome (VAS-P), the average daily dosage of gabapentin, and the results of the neuropathic dysfunctional scale (modified version, NDSm), Pittsburgh Sleep Quality Index, PSQI), Global Rating of Change Scale (GROC), the results of electroneuromyography (ENMG). The total duration of the observation and treatment period was 2 months.Results. After 2 months of therapy in the main group of patients, compared with the control group, there was significantly more complete pain control (VAS-P: 3.0 ± 0.9 vs 3.6 ± 0.8), a decrease in the average daily dosage of gabapentin (390 vs 500 mg/day), reduction in the severity of clinical manifestations of polyneuropathic syndrome (NDSm: 4.4 ± 1.0 vs 4.9 ± 1.0 points) and improvement in sleep quality (PSQI: 6.8 ± 1.3 vs 7.9 ± 1.7). According to ENMG data, patients in the main group showed a significant improvement in the neurophysiological parameters of both motor and sensory fibers, which was significantly more pronounced compared to the control group. A significantly larger proportion of patients in the main group assessed the improvement from the therapy as ‘pronounced’ (GROC: 10/33.3 % vs 6/20.0 %).Conclusions. The use of ipidacrine in complex therapy of patients with DPN can significantly reduce the clinical manifestations of disease and improve the neurophysiological parameters of the peripheral nerves of the lower extremities. Ipidacrine can be considered as a basic drug for the treatment of patients with neurological complications of diabetes mellitus.
- 27 April 2024
- Published by Alfmed LLC in Medical alphabet
- No. 2,p. 26-32
Open-label observational study of effectiveness and tolerability of ipidacrine in treatment of patients with diabetic polyneuropathy (DIAMANT study)
Diabetic polyneuropathy (DPN) is one of the most common complications of diabetes mellitus, leading to the development of flaccid paresis, neuropathic pain syndrome, sensitive ataxia, as well as trophic disorders in the distal parts of the lower extremities.The purpose of the randomized, open-label, comparative, prospective study was to evaluate the effectiveness and tolerability of ipidacrine in the complex treatment of patients with DPN.Materials and methods. Patients with DPN (n = 60) were randomized into 2 groups. Both groups received basic therapy (alpha-lipoic acid, B vitamins, gabapentin); in the treatment of patients of the main group (n = 30), in addition, ipidacrine was used (Ipidacrine-SZ, North Star Co., Russia). We have analyzed the intensity of pain syndrome (VAS-P), the average daily dosage of gabapentin, and the results of the neuropathic dysfunctional scale (modified version, NDSm), Pittsburgh Sleep Quality Index, PSQI), Global Rating of Change Scale (GROC), the results of electroneuromyography (ENMG). The total duration of the observation and treatment period was 2 months.Results. After 2 months of therapy in the main group of patients, compared with the control group, there was significantly more complete pain control (VAS-P: 3.0 ± 0.9 vs 3.6 ± 0.8), a decrease in the average daily dosage of gabapentin (390 vs 500 mg/day), reduction in the severity of clinical manifestations of polyneuropathic syndrome (NDSm: 4.4 ± 1.0 vs 4.9 ± 1.0 points) and improvement in sleep quality (PSQI: 6.8 ± 1.3 vs 7.9 ± 1.7). According to ENMG data, patients in the main group showed a significant improvement in the neurophysiological parameters of both motor and sensory fibers, which was significantly more pronounced compared to the control group. A significantly larger proportion of patients in the main group assessed the improvement from the therapy as ‘pronounced’ (GROC: 10/33.3 % vs 6/20.0 %).Conclusions. The use of ipidacrine in complex therapy of patients with DPN can significantly reduce the clinical manifestations of disease and improve the neurophysiological parameters of the peripheral nerves of the lower extremities. Ipidacrine can be considered as a basic drug for the treatment of patients with neurological complications of diabetes mellitus.